Cannabinoid receptor 2 (CB2) is a G-protein coupled receptor predominantly expressed on immune cells (macrophages, T cells, B cells, NK cells, mast cells, neutrophils), microglia, osteoblasts, osteoclasts, and peripheral tissues. CB2 activation drives anti-inflammatory and pro-resolution effects through modulation of cytokine production, immune cell migration, and efferocytosis, without producing the psychoactive effects mediated by CB1 receptors. CB2 is the primary target through which endocannabinoids, specialized pro-resolving mediators (SPMs), and exogenous cannabinoids resolve inflammation and promote tissue repair.
Think of CB2 receptors as fire station dispatch systems distributed throughout the immune response zones rather than in the brain's central command. When inflammation flares (the fire starts), immune cells rush to the scene like emergency responders. CB2 receptors are the dispatch radios that, when activated, tell the fire crews: "Start winding down operations, switch from fighting the blaze to cleanup mode, and make sure you properly dispose of all the debris before you leave."
The dispatcher (CB2) doesn't stop the initial alarm or prevent firefighters from arriving—it manages the resolution phase. It signals M1 macrophages (the aggressive fire-hose crews) to transform into M2 macrophages (the cleanup and reconstruction teams). It tells neutrophils to stop arriving at the scene. It ensures that apoptotic cells (burned debris) get properly cleared through efferocytosis rather than left to rot and cause secondary damage. Crucially, this dispatch system is only in the peripheral stations (immune tissues), not in the central fire department headquarters (the brain), which is why activating CB2 doesn't make you feel high—you're coordinating the cleanup crews, not affecting the chief's office.
CB2 receptors are seven-transmembrane domain G-protein coupled receptors (GPCRs) that couple primarily to Gi/o proteins. The signaling cascade proceeds as follows:
Primary Signaling Pathway:
- Endocannabinoid binding (2-AG > anandamide) or exocannabinoid activation (β-caryophyllene, CBD indirect effects)
- CB2 couples to Gi/o protein → inhibits adenylyl cyclase
- Decreased cAMP production → reduced PKA activation
- Simultaneously activates MAPK pathways (ERK1/2, p38, JNK)
- In macrophages: activates PI3K/Akt pathway → promotes M2 polarization
Macrophage-Specific Effects:
- CB2 activation → ↓ NF-κB translocation → ↓ pro-inflammatory gene transcription
- ↓ TNF-α, IL-6, IL-1β, IL-12 production
- ↑ IL-10, TGF-β, IL-4 production (M2 cytokines)
- Enhanced expression of mannose receptor (CD206), arginase-1, FIZZ1 (M2 markers)
- ↑ efferocytosis via enhanced phosphatidylserine recognition and phagocytic cup formation
Neutrophil Effects:
- CB2 activation → ↓ CXCR2 surface expression
- ↓ chemotaxis toward CXCL1, CXCL8
- ↓ adhesion molecule expression (L-selectin shedding)
- Reduced migration across endothelium
Mast Cell Effects:
- CB2 activation → ↓ degranulation
- ↓ histamine release
- ↓ leukotriene production (via inhibition of 5-LOX pathway)
Microglial Effects (CNS-resident immune cells):
- CB2 upregulated 10-100 fold during neuroinflammation
- Activation → shift from M1-like (inflammatory) to M2-like (anti-inflammatory) phenotype
- ↓ NO production, ↓ ROS generation
- ↑ clearance of amyloid-β and cellular debris
SPM-CB2 Synergy:
- Resolvins (RvD1, RvD2, RvE1) enhance CB2 signaling via ALX-FPR2 receptor co-activation
- Maresins (MaR1) amplify CB2-mediated efferocytosis
- Omega-3-derived endocannabinoid epoxides (epoxyeicosatetraenoyl ethanolamides) directly activate CB2
graph TD
A["2-AG/Anandamide/β-caryophyllene"] -->|Binds| B[CB2 Receptor]
B --> C[Gi/o Protein Coupling]
C --> D["↓ Adenylyl Cyclase"]
C --> E[MAPK Activation]
D --> F["↓ cAMP → ↓ PKA"]
E --> G[ERK1/2, p38, JNK]
F --> H["↓ NF-κB Activity"]
G --> I[M2 Polarization Genes]
H --> J["↓ TNF-α, IL-6, IL-1β"]
I --> K["↑ IL-10, TGF-β, Arginase-1"]
K --> L[Resolution of Inflammation]
J --> L
B --> M[On Neutrophils]
M --> N["↓ CXCR2 Expression"]
N --> O["↓ Chemotaxis & Migration"]
B --> P[On Mast Cells]
P --> Q["↓ Degranulation"]
Q --> R["↓ Histamine Release"]
B --> S[On Microglia]
S --> T["M1→M2 Phenotype Shift"]
T --> U["↓ Neuroinflammation"]
CB2 receptors represent a critical therapeutic target for resolution-based inflammation management without CNS side effects, making them central to cPNI interventions across multiple systems.
Patient Populations:
- Chronic inflammatory conditions: rheumatoid arthritis, inflammatory bowel disease, psoriasis, chronic pain syndromes
- Neurodegenerative diseases: Alzheimer's, Parkinson's, multiple sclerosis (microglial CB2 upregulation)
- Metabolic dysfunction: obesity-associated inflammation, insulin resistance, NAFLD
- Wound healing impairments: diabetic ulcers, post-surgical recovery, sports injuries
- Allergic conditions: mast cell activation syndrome, asthma, allergic rhinitis
Metamodel Connections:
- Metamodel 1 (Selfish Immune System): CB2 activation shifts the immune system from self-preservation mode (continued inflammation to protect against perceived threat) to resolution mode (tissue repair prioritized over continued defense)
- Metamodel 3 (Chronic Low-Grade Inflammation): CB2 agonism addresses the failure to properly resolve inflammatory episodes that characterizes modern chronic inflammation
- Metamodel 5 (Evolutionary Mismatch): Modern diets low in omega-3s reduce endocannabinoid substrate availability; ancestral diets high in EPA/DHA naturally supported CB2-mediated resolution
Clinical Biomarkers:
- CB2 receptor expression on peripheral blood mononuclear cells (PBMC) can be measured via flow cytometry
- Endocannabinoid tone: measure 2-AG and anandamide levels (typical range 2-AG: 4-12 ng/mL; anandamide: 0.4-2.0 ng/mL)
- Resolution indices: efferocytosis capacity, M1/M2 macrophage ratio, SPM levels
Intervention Implications:
- Omega-3 optimization (EPA 2-3g/day, DHA 1-2g/day): provides substrate for both endocannabinoid synthesis and SPM production, creating synergistic CB2 activation
- Exocannabinoid supplementation: β-caryophyllene (40-200mg/day from black pepper, oregano, rosemary, clove extracts), hemp oil (CBD 25-100mg/day)
- PEA supplementation (300-600mg twice daily): indirect CB2 activation via PPAR-α and entourage effects
- Herbal CB2 agonists: oregano oil, cumin, rosemary extract, calendula
- Lifestyle: exercise (especially resistance training) upregulates CB2 on muscle macrophages; sauna therapy enhances endocannabinoid production
- Avoid CB2 antagonists: chronic NSAID use may interfere with endocannabinoid metabolism
Clinical Threshold Insights:
- CB2 upregulation begins within 2-4 hours of inflammatory stimulus
- Peak CB2 expression on microglia: 48-72 hours post-injury
- Therapeutic window for exocannabinoid intervention: ideally during proliferative phase of wound healing (days 3-14)
- CB2 receptors are 10-100 times more abundant on immune cells than CB1, with highest expression on B cells, NK cells, and macrophages
- CB2 expression on microglia is virtually absent at baseline but upregulates 10-100 fold during neuroinflammation (e.g., Alzheimer's, stroke, traumatic brain injury)
- β-caryophyllene from black pepper is a full CB2 agonist (EC50 ~155 nM) and the only dietary terpene known to directly activate cannabinoid receptors
- CB2 activation promotes M2 macrophage polarization with increased arginase-1 expression (>3-fold) and enhanced efferocytosis capacity (>60% increase in apoptotic cell clearance)
- 2-AG is the predominant endogenous CB2 ligand (100-1000× more abundant than anandamide in immune tissues) and is synthesized from both omega-6 (arachidonic acid) and omega-3 (EPA, DHA) sources
- Omega-3 fatty acids increase CB2 receptor expression on macrophages by 40-70% and enhance receptor sensitivity through membrane raft restructuring
- PEA (palmitoylethanolamide) enhances CB2 signaling through PPAR-α activation and the entourage effect (increasing anandamide availability by inhibiting FAAH enzyme)
- CB2 knockout mice show enhanced inflammatory responses, delayed wound healing, and increased susceptibility to neurodegeneration
- Clinical CB2 agonist compounds (e.g., lenabasum, GW842166X) show efficacy in reducing inflammatory pain with IC50 values 100-1000× more selective for CB2 vs CB1
- Herbs with CB2-activating compounds: hemp oil (CBD 25-100mg triggers indirect CB2 effects), oregano (carvacrol, β-caryophyllene), cumin (cuminaldehyde), rosemary (carnosic acid, rosmarinic acid), clove (eugenol, β-caryophyllene)
- CB2 receptors are also expressed on osteoblasts and osteoclasts, where activation promotes bone formation and inhibits bone resorption (relevant for osteoporosis, fracture healing)
- During pregnancy, CB2 upregulation on uterine immune cells is essential for maternal-fetal tolerance
- CB1 — CB1 is primarily CNS/neuronal with psychoactive effects; CB2 is peripheral/immune-dominant; both are activated by endocannabinoids but have opposite tissue distributions and functional outcomes in inflammation
- Endocannabinoid System — CB2 is the primary peripheral receptor of this system; works with CB1, endocannabinoids, and metabolizing enzymes to maintain immune homeostasis
- macrophages — CB2 is highly expressed on macrophages (especially M1 phenotype); activation drives M1→M2 transition, the cornerstone of inflammation resolution
- M2 macrophages — CB2 signaling is one of the primary drivers of M2 polarization; increases arginase-1, CD206, IL-10 production, and efferocytosis capacity
- M1 macrophages — CB2 activation suppresses M1 phenotype by inhibiting NF-κB-driven transcription of TNF-α, IL-6, IL-1β, and iNOS
- endocannabinoids — 2-AG and anandamide are endogenous CB2 ligands; levels increase during inflammation as homeostatic resolution signal
- 2-ag — primary endogenous CB2 agonist (100-1000× more abundant than anandamide); synthesized from arachidonic acid via diacylglycerol lipase
- omega-3 fatty acids — EPA/DHA serve as substrates for omega-3-derived endocannabinoids (e.g., DHEA, EPEA) that activate CB2 and enhance receptor expression on immune cells
- resolvins — EPA/DHA-derived resolvins (RvD1, RvE1) work synergistically with CB2 signaling via ALX-FPR2 receptor to amplify resolution pathways
- protectins — DHA-derived protectins (PD1, PDX) enhance CB2-mediated anti-inflammatory effects and neuroprotection in microglia
- maresins — DHA-derived maresins (MaR1) potentiate CB2-driven efferocytosis and tissue regeneration; both activate overlapping signaling cascades
- PEA — palmitoylethanolamide enhances CB2 signaling indirectly through PPAR-α activation and entourage effect (increases anandamide by inhibiting FAAH degradation)
- exocannabinoids — external cannabinoids like β-caryophyllene (dietary terpene) directly activate CB2; CBD indirectly enhances CB2 function through allosteric modulation
- mast cell — CB2 activation on mast cells inhibits degranulation, reduces histamine and leukotriene release; therapeutic for allergies and MCAS
- neutrophils — CB2 signaling reduces neutrophil chemotaxis (via CXCR2 downregulation), adhesion, and migration to inflammatory sites; prevents excessive tissue damage
- microglia — CB2 is dramatically upregulated on activated microglia during neuroinflammation; activation shifts microglia from neurotoxic to neuroprotective phenotype
- TNF-α — CB2 activation suppresses TNF-α production from macrophages, microglia, and T cells by inhibiting NF-κB nuclear translocation
- IL-6 — CB2 signaling reduces IL-6 production and secretion from immune cells; lowers systemic inflammation markers
- IL-10 — CB2 activation increases IL-10 (anti-inflammatory cytokine) production from M2 macrophages and Tregs
- chronic pain — CB2 activation reduces inflammatory and neuropathic pain without CNS side effects; acts on immune cells in dorsal root ganglia and spinal cord
- wound healing — CB2 signaling is essential in all phases: limits initial inflammation, promotes M2-mediated proliferation, and supports remodeling through collagen regulation
- resoleomics — CB2 receptors are central mediators of the resolution phase; activated by both endocannabinoids and SPMs to drive active resolution programming
- Efferocytosis — CB2 activation enhances macrophage recognition and engulfment of apoptotic cells via phosphatidylserine receptor upregulation; critical for debris clearance
- NF-κB — CB2 signaling inhibits NF-κB nuclear translocation and DNA binding, reducing transcription of pro-inflammatory genes (TNF-α, IL-6, COX-2, iNOS)
- MAPK pathway — CB2 activates ERK1/2 and p38 MAPK to drive M2 polarization genes while simultaneously inhibiting JNK-mediated pro-inflammatory pathways
- osteoblasts — CB2 receptors on osteoblasts promote bone formation; CB2 agonists increase osteoblast differentiation and mineralization
- osteoclast — CB2 activation inhibits osteoclast formation and bone resorption; therapeutic target for osteoporosis
- Specialised pro-resolving mediators — SPMs (resolvins, protectins, maresins) and CB2 receptors work in concert as the "resolution duo"; SPMs enhance CB2 expression and sensitivity
- inflammatory bowel disease — CB2 is upregulated on intestinal immune cells in IBD; CB2 agonists reduce colitis severity in preclinical models
- Multiple Sclerosis — CB2 upregulation on CNS microglia and infiltrating immune cells; CB2 activation reduces demyelination and neuroinflammation
- Alzheimer's Disease — CB2 upregulation on microglia surrounding amyloid plaques; activation enhances Aβ clearance and reduces neuroinflammation
- neuroinflammation — CB2 is the primary cannabinoid receptor mediating anti-inflammatory effects in the CNS; upregulated on microglia during all neurodegenerative processes
- arachidonic acid — substrate for 2-AG synthesis; also generates pro-inflammatory eicosanoids, creating competitive pathways that CB2 activation can redirect toward resolution
- PPAR-alpha — PEA activates PPAR-α, which transcriptionally upregulates CB2 receptor expression and enhances endocannabinoid signaling
- chronic inflammation — CB2 dysfunction or insufficient endocannabinoid tone contributes to failure of inflammation resolution characteristic of chronic inflammatory states
- Module 3 (Immune System & Inflammation)
- Module 5 (Neuroendocrinology & Pain)